Abhijit Dasgupta

Mr. Abhijit Dasgupta


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
JYJay M. Yarbro
Jay M. Yarbro
XHXian Han
Xian Han
ADAbhijit Dasgupta
Abhijit Dasgupta
KYKa Yang
Ka Yang
DLDanting Liu
Danting Liu
JPJunmin Peng
Junmin Peng
Murine models of Alzheimer’s disease (AD) are crucial for elucidating disease mechanisms but have limitations in fully representing AD molecular complexities. Here we present the comprehensive, age-dependent brain proteome and phosphoproteome across multiple mouse models of amyloidosis. We identified shared pathways by integrating with human metadata and prioritized components by multi-omics analysis. Collectively, two commonly used models (5xFAD and APP-KI) replicate 30% of the human protein alterations; additional genetic incorporation of tau and splicing pathologies increases this similarity to 42%. We dissected the proteome-transcriptome inconsistency in AD and 5xFAD mouse brains, revealing that inconsistent proteins are enriched within amyloid plaque microenvironment (amyloidome). Our analysis of the 5xFAD proteome turnover demonstrates that amyloid formation delays the degradation of amyloidome components, including Aβ-binding proteins and autophagy/lysosomal proteins. Our proteomic strategy defines shared AD pathways, identifies potential targets, and underscores that protein turnover contributes to proteome-transcriptome discrepancies during AD progression.

14 September 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DPDebjyoti Paul
Debjyoti Paul
ADAbhijit Dasgupta
Abhijit Dasgupta
RDRajat Kumar De
Rajat Kumar De
In contrast with normal cells, most of the cancer cells depend on aerobic glycolysis for energy production in the form of adenosine triphosphate (ATP) bypassing mitochondrial oxidative phosphorylation. Moreover, compared to normal cells, cancer cells exhibit higher consumption of glucose with higher production of lactate. Again, higher rate of glycolysis provides the necessary glycolytic intermediary precursors for DNA, protein and lipid synthesis to maintain high active proliferation of the tumor cells. In this scenario, classical control theory based approach may be useful to explore the altered dynamics of the cancer cells. Since the dynamics of the cancer cells is different from that of the normal cells, understanding their dynamics may lead to development of novel therapeutic strategies. We have developed a model based on the state space equations of classical control theory along with an order reduction technique to mimic the actual dynamic behavior of mammalian central carbon metabolic (CCM) pathway in normal cells. Here, we have modified Michaelis Menten kinetic equation to incorporate feedback mechanism along with perturbations and cross talks associated with a metabolic pathway. Furthermore, we have perturbed the proposed model to reduce the mitochondrial oxidative phosphorylation. Thereafter, we have connected proportional-integral (PI) controller(s) with the model for tuning it to behave like the CCM pathway of a cancer cell. This methodology allows one to track the altered dynamics mediated by different enzymes. The proposed model successfully mimics all the probable dynamics of the CCM pathway in normal cells. Moreover, experimental results demonstrate that in cancer cells, a coordination among enzymes catalyzing pentose phosphate pathway and intermediate glycolytic enzymes along with switching of pyruvate kinase (M2 isoform) plays an important role to maintain their altered dynamics.

1 November 2015
Verified
Conference Paper
Closed access
ADAbhijit Dasgupta
Abhijit Dasgupta
RDRitankar Das
Ritankar Das
LNLosiana Nayak
Losiana Nayak
RDRajat K. De
Rajat K. De
Epileptogenic brain connectivity networks are altered compared to normal ones. Here, we have investigated the properties of epileptogenic networks by applying graph theoretical, statistical and machine learning approaches to the resting state electroencephalography (EEG) recordings obtained from 30 normal volunteers and 51 patients suffering from generalized epilepsy. In the case of epileptic patients, we have found that the brain networks behave like random networks. There is some loss in node connectivity. Hub nodes are more affected during epilepsy. Hence, the epileptogenic networks show less clustering coefficient than normal ones. In addition, we have identified 11 specific regions of brains and ten most significant connections among them as an epileptogenic signature by feature extraction. The ten most significant features are used to classify 81 sample data sets into two classes, i.e., epileptogenic and normal, with 79.01% accuracy. The highly probable eleven regions of human brain according to the positions of electrodes and connections among them may lead to a progress in the clinical treatment of epileptic patients.

18 February 2025 in Journal of the American Medical Informatics Association
Verified
Journal Article
Closed access
ABAbhisek Bakshi
Abhisek Bakshi
KGKaustav Gangopadhyay
Kaustav Gangopadhyay
SBSujit Basak
Sujit Basak
RDRajat K De
Rajat K De
SSSouvik Sengupta
Souvik Sengupta
ADAbhijit Dasgupta
Abhijit Dasgupta
Objective: This study addresses the significant challenges posed by emerging SARS-CoV-2 variants, particularly in developing diagnostics and therapeutics. Drug repurposing is investigated by identifying critical regulatory proteins impacted by the virus, providing rapid and effective therapeutic solutions for better disease management. Materials and Methods: We employed a comprehensive approach combining mathematical modeling and efficient parameter estimation to study the transient responses of regulatory proteins in both normal and virus-infected cells. Proportional-integral-derivative (PID) controllers were used to pinpoint specific protein targets for therapeutic intervention. Additionally, advanced deep learning models and molecular docking techniques were applied to analyse drug-target and drug-drug interactions, ensuring both efficacy and safety of the proposed treatments. This approach was applied to a case study focused on the cytokine storm in COVID-19, centering on Angiotensin-converting enzyme 2 (ACE2), which plays a key role in SARS-CoV-2 infection. Results: Our findings suggest that activating ACE2 presents a promising therapeutic strategy, whereas inhibiting AT1R seems less effective. Deep learning models, combined with molecular docking, identified Lomefloxacin and Fostamatinib as stable drugs with no significant thermodynamic interactions, suggesting their safe concurrent use in managing COVID-19-induced cytokine storms. Discussion: The results highlight the potential of ACE2 activation in mitigating lung injury and severe inflammation caused by SARS-CoV-2. This integrated approach accelerates the identification of safe and effective treatment options for emerging viral variants. Conclusion: This framework provides an efficient method for identifying critical regulatory proteins and advancing drug repurposing, contributing to the rapid development of therapeutic strategies for COVID-19 and future global pandemics.

26 May 2016 in Molecular BioSystems
Verified
Journal Article
Closed access
PDF file
ADAbhijit Dasgupta
Abhijit Dasgupta
DPDebjyoti Paul
Debjyoti Paul
RDRajat Kumar De
Rajat Kumar De
Dynamics of large nonlinear complex systems, like metabolic networks, depend on several parameters. A metabolic pathway may switch to another pathway in accordance with the current state of parameters in both normal and cancer cells. Here, most of the parameter values are unknown to us. A fuzzy logic controller (FLC) has been developed here for the purpose of modeling metabolic networks by approximating the reasons for the behaviour of a system and applying expert knowledge to track switching between metabolic pathways. The simulation results can track the switching between glycolysis and gluconeogenesis, as well as glycolysis and pentose phosphate pathways (PPP) in normal cells. Unlike normal cells, pyruvate kinase (M2 isoform) (PKM2) switches alternatively between its two oligomeric forms, i.e. an active tetramer and a relatively low activity dimer, in cancer cells. Besides, there is a coordination among PKM2 switching and enzymes catalyzing PPP. These phenomena help cancer cells to maintain their high energy demand and macromolecular synthesis. However, the reduction of initial adenosine triphosphate (ATP) to a very low concentration, decreasing initial glucose uptake, destroying coordination between glycolysis and PPP, and replacement of PKM2 by its relatively inactive oligomeric form (dimer) or inhibition of the translation of PKM2 may destabilize the mutated control mechanism of the mammalian central carbon metabolic (CCM) pathway in cancer cells. The performance of the model is compared appropriately with some existing ones.

25 October 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
JYJay M. Yarbro
Jay M. Yarbro
XHXian Han
Xian Han
ADAbhijit Dasgupta
Abhijit Dasgupta
KYKa Yang
Ka Yang
DLDanting Liu
Danting Liu
JPJunmin Peng
Junmin Peng
Murine models of Alzheimer’s disease (AD) are crucial for elucidating disease mechanisms but have limitations in fully representing AD molecular complexities. We comprehensively profiled age-dependent brain proteome and phosphoproteome ( n > 10,000 for both) across multiple mouse models of amyloidosis. We identified shared pathways by integrating with human metadata, and prioritized novel components by multi-omics analysis. Collectively, two commonly used models (5xFAD and APP-KI) replicate 30% of the human protein alterations; additional genetic incorporation of tau and splicing pathologies increases this similarity to 42%. We dissected the proteome-transcriptome inconsistency in AD and 5xFAD mouse brains, revealing that inconsistent proteins are enriched within amyloid plaque microenvironment (amyloidome). Determining the 5xFAD proteome turnover demonstrates that amyloid formation delays the degradation of amyloidome components, including Aβ-binding proteins and autophagy/lysosomal proteins. Our proteomic strategy defines shared AD pathways, identify potential new targets, and underscores that protein turnover contributes to proteome-transcriptome discrepancies during AD progression.